<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VANOS - fluocinonide cream </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1>VANOS<span class="Sup">®</span><br> (fluocinonide) Cream, 0.1%</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx Only</span></p>
<p>FOR TOPICAL USE ONLY<br>NOT FOR OPHTHALMIC, ORAL, OR INTRAVAGINAL USE</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">VANOS (fluocinonide) Cream, 0.1% contains fluocinonide, a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents. Fluocinonide has the chemical name 6 alpha, 9 alpha-difluoro-11 beta, 21-dihydroxy-16 alpha, 17 alpha-isopropylidenedioxypregna-1, 4-diene-3,20-dione 21-acetate. Its chemical formula is C<span class="Sub">26</span>H<span class="Sub">32</span>F<span class="Sub">2</span>O<span class="Sub">7</span> and it has a molecular weight of 494.58.</p>
<p>It has the following chemical structure:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=34b91547-31f6-4043-b91c-16c9ebd81349&amp;name=vanos-01.jpg"></div>
<p>Fluocinonide is an almost odorless white to creamy white crystalline powder. It is practically insoluble in water and slightly soluble in ethanol.</p>
<p>Each gram of VANOS Cream contains 1 mg micronized fluocinonide in a cream base of propylene glycol USP, dimethyl isosorbide, glyceryl stearate (and) PEG-100 stearate, glyceryl monostearate NF, purified water USP, carbopol 980 NF, diisopropanolamine, and citric acid USP.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="clin"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Like other topical corticosteroids, VANOS (fluocinonide) Cream, has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of topical corticosteroids, in general, is unclear. However, corticosteroids are thought to act by induction of phospholipase A<span class="Sub">2</span> inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachadonic acid. Arachadonic acid is released from membrane phospholipids by phospholipase A<span class="Sub">2</span>.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="section-3.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle and the integrity of the epidermal barrier. Topical corticosteroids can be absorbed from normal intact skin. <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> and/or other disease processes in the skin may increase percutaneous absorption.</p>
<p>Vasoconstrictor studies performed with VANOS Cream, 0.1% in healthy subjects indicate that it is in the super-high range of potency as compared with other topical corticosteroids; however, similar <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">blanching</span> scores do not necessarily imply therapeutic equivalence.</p>
<p>Application of VANOS Cream, 0.1% twice daily for 14 days in 18 adult patients with plaque-type <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> (10–50% BSA, mean 19.6% BSA) showed demonstrable HPA-axis suppression in 2 patients (with 12% and 25% BSA) where the criterion for HPA-axis suppression is a serum cortisol level of less than or equal to 18 micrograms per deciliter 30 minutes after stimulation with cosyntropin (ACTH<span class="Sub">1–24</span>) (<span class="Bold">See <a href="#gen">PRECAUTIONS: General</a></span> and <span class="Bold"><a href="#pediatric">Pediatric Use</a></span>).</p>
<p>HPA-axis suppression has not been evaluated in <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> patients who are less than 18 years of age. HPA-axis suppression has been evaluated in pediatric patients with <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span> 12 to 18 years of age (See <span class="Bold"><a href="#pediatric">PRECAUTIONS: Pediatric Use</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="clins"></a><a name="section-4"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">Two adequate and well-controlled efficacy and safety studies of VANOS Cream have been completed, one in adult patients with plaque-type <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> (Table 1), and one in adult patients with <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span> (Table 2). In each of these studies, patients with between 2% and 10% body surface area involvement at Baseline treated all affected areas either once daily or twice daily with VANOS Cream for 14 consecutive days. The primary measure of efficacy was the proportion of patients whose condition was cleared or almost cleared at the end of treatment. The results of these studies are presented in the tables below as percent and number of patients achieving treatment success at Week 2.</p>
<a name="i39dd02c7-d759-40b6-8c70-89170c91cf92"></a><table width="100%">
<caption><span>Table 1: Plaque-Type <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">Psoriasis</span> in Adults</span></caption>
<col align="left" valign="bottom" width="20%">
<col align="center" valign="bottom" width="20%">
<col align="center" valign="bottom" width="20%">
<col align="center" valign="bottom" width="20%">
<col align="center" valign="bottom" width="20%">
<thead><tr class="First Last">
<th class="Lrule" align="left"></th>
<th class="Lrule" align="center">VANOS Cream,<br><span class="Italics">once daily</span><br>(n=107)</th>
<th class="Lrule" align="center">Vehicle,<br><span class="Italics">once daily</span><br>(n=54)</th>
<th class="Lrule" align="center">VANOS Cream,<br><span class="Italics">twice daily</span><br>(n=107)</th>
<th class="Lrule Rrule" align="center">Vehicle,<br><span class="Italics">twice daily</span><br>(n=55)</th>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Cleared or almost cleared</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="left">Patients cleared</td>
<td class="Lrule" align="center">0 (0)</td>
<td class="Lrule" align="center">0 (0)</td>
<td class="Lrule" align="center">6 (6%)</td>
<td class="Lrule Rrule" align="center">0 (0)</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">Patients achieving treatment success<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</td>
<td class="Lrule" align="center">19 (18%)</td>
<td class="Lrule" align="center">4 (7%)</td>
<td class="Lrule" align="center">33 (31%)</td>
<td class="Lrule Rrule" align="center">3 (5%)</td>
</tr>
</tbody>
</table>
<a name="i1f46577b-6273-4f11-8747-fd8e63b4c980"></a><table width="100%">
<caption><span>Table 2: <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">Atopic Dermatitis</span> in Adults</span></caption>
<col align="left" valign="bottom" width="20%">
<col align="center" valign="bottom" width="20%">
<col align="center" valign="bottom" width="20%">
<col align="center" valign="bottom" width="20%">
<col align="center" valign="bottom" width="20%">
<thead><tr class="First Last">
<th class="Lrule" align="left"></th>
<th class="Lrule" align="center">VANOS Cream,<br><span class="Italics">once daily</span><br>(n=109)</th>
<th class="Lrule" align="center">Vehicle,<br><span class="Italics">once daily</span><br>(n=50)</th>
<th class="Lrule" align="center">VANOS Cream,<br><span class="Italics">twice daily</span><br>(n=102)</th>
<th class="Lrule Rrule" align="center">Vehicle,<br><span class="Italics">twice daily</span><br>(n=52)</th>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Cleared or almost cleared</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="left">Patients cleared</td>
<td class="Lrule" align="center">11 (10%)</td>
<td class="Lrule" align="center">0 (0)</td>
<td class="Lrule" align="center">17 (17%)</td>
<td class="Lrule Rrule" align="center">0 (0)</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">Patients achieving treatment success<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>
</td>
<td class="Lrule" align="center">64 (59%)</td>
<td class="Lrule" align="center">6 (12%)</td>
<td class="Lrule" align="center">58 (57%)</td>
<td class="Lrule Rrule" align="center">10 (19%)</td>
</tr>
</tbody>
</table>
<p>No efficacy studies have been conducted to compare VANOS (fluocinonide) Cream, 0.1% with any other topical corticosteroid product, including fluocinonide cream 0.05%.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">VANOS (fluocinonide) Cream, 0.1%, is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in patients 12 years of age or older (<span class="Bold">See <a href="#pediatric">PRECAUTIONS: Pediatric Use</a></span>).</p>
<p>Treatment beyond 2 consecutive weeks is not recommended and the total dosage should not exceed 60 g/week because the safety of VANOS Cream for longer than 2 weeks has not been established and because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis. Therapy should be discontinued when control of the disease is achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary. Do not use more than half of the 120 g tube per week.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">VANOS Cream is contraindicated in those patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the components of the preparation.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="precau"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="gen"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for gluococorticosteroid insufficiency after withdrawal of treatment. Manifestations of Cushing's syndrome, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on treatment. Use of more than one corticosteroid-containing product at the same time may increase total systemic glucocorticoid exposure. In addition, use of VANOS Cream for longer than 2 weeks may also suppress the immune system (<span class="Bold">see <a href="#cmif">PRECAUTIONS: Carcinogenesis, Mutagenesis, and Impairment of Fertility</a></span>).</p>
<p>Patients applying a topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA-axis suppression. This may be done by using cosyntropin (ACTH<span class="Sub">1–24</span>) stimulation testing. Patients should not be treated with VANOS Cream for more than 2 weeks at a time and only small areas should be treated at any time due to the increased risk of HPA-axis suppression.</p>
<p>If HPA-axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid. Recovery of HPA-axis function is generally prompt upon discontinuation of topical corticosteroids. Infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur requiring supplemental systemic corticosteroids. For information on systemic supplementation, see prescribing information for those products.</p>
<p>Application of VANOS Cream, 0.1% twice daily for 14 days in 18 adult patients with plaque-type <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> (10–50% BSA, mean 19.6% BSA) and 31 adult patients (17 treated once daily; 14 treated twice daily) with <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span> (2–10% BSA, mean 5% BSA) showed demonstrable HPA-axis suppression in 2 patients with <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> (with 12% and 25% BSA) and 1 patient with <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span> (treated once daily, 4% BSA) where the criterion for HPA-axis suppression is a serum cortisol level of less than or equal to 18 micrograms per deciliter 30 minutes after stimulation with cosyntropin (ACTH<span class="Sub">1–24</span>) (<span class="Bold">See <a href="#clin">CLINICAL PHARMACOLOGY</a></span> ).</p>
<p>Controlled clinical efficacy studies of VANOS Cream in pediatric patients younger than 17 years of age have not been conducted; (See <span class="Bold"><a href="#pediatric">PRECAUTIONS: Pediatric Use</a></span>).</p>
<p>HPA-axis suppression has not been evaluated in <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> patients who are less than 18 years of age.</p>
<p>Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> ratios. (See <span class="Bold"><a href="#pediatric">PRECAUTIONS: Pediatric Use</a></span>).</p>
<p>If irritation develops, VANOS Cream should be discontinued and appropriate therapy instituted. <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Allergic contact dermatitis</span> with corticosteroids is usually diagnosed by observing failure to heal rather than noting a clinical exacerbation as with most topical products not containing corticosteroids. Such an observation should be corroborated with appropriate diagnostic patch testing.</p>
<p>If concomitant <span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">skin infections</span> are present or develop, an appropriate antifungal or antibacterial agent should be used. If a favorable response does not occur promptly, use of VANOS Cream should be discontinued until the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> has been adequately controlled.</p>
<p>VANOS Cream should not be used in the treatment of <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span> or <span class="product-label-link" type="condition" conceptid="135032" conceptname="Dermatitis due to substances taken internally">perioral dermatitis</span>, and should not be used on the face, groin, or axillae.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.2"></a><p></p>
<h2>Information for the Patient</h2>
<p class="First">Patients using VANOS Cream should receive the following information and instructions. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or unintended effects:</p>
<dl>
<dt>1)</dt>
<dd>VANOS Cream is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes. It should not be used on the face, groin, and underarms.</dd>
<dt>2)</dt>
<dd>VANOS Cream should not be used for any disorder other than that for which it was prescribed.</dd>
<dt>3)</dt>
<dd>The treated skin area should not be bandaged or otherwise covered or wrapped, so as to be occlusive unless directed by the physician.</dd>
<dt>4)</dt>
<dd>Patients should report to their physician any signs of local adverse reactions.</dd>
<dt>5)</dt>
<dd>Other corticosteroid-containing products should not be used with VANOS Cream without first talking to the physician.</dd>
<dt>6)</dt>
<dd>As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen in 2 weeks, the patient should be instructed to contact a physician. The safety of the use of VANOS Cream for longer than 2 weeks has not been established.</dd>
<dt>7)</dt>
<dd>Patients should be informed to not use more than 60 g per week of VANOS Cream. Do not use more than half of the 120 g tube per week.</dd>
<dt>8)</dt>
<dd>Patients should inform their physicians that they are using VANOS Cream if surgery is contemplated.</dd>
<dt>9)</dt>
<dd>Patients should wash their hands after applying medication.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-7.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">The cosyntropin (ACTH<span class="Sub">1–24</span>) stimulation test may be helpful in evaluating patients for HPA-axis suppression.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="cmif"></a><a name="section-7.4"></a><p></p>
<h2>Carcinogenesis, M utagenesis, and Impairment of Fertility</h2>
<p class="First">Long-term animal studies have not been performed to evaluate the carcinogenic potential of VANOS Cream because of severe <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> induced in a 13-week dermal rat study. The effects of fluocinonide on fertility have not been evaluated.</p>
<p>Fluocinonide revealed no evidence of mutagenic or clastogenic potential based on the results of two <span class="Italics">in vitro</span> genotoxicity tests (Ames test and chromosomal aberration assay using human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>). However, fluocinonide was positive for clastogenic potential when tested in the <span class="Italics">in vivo</span> mouse micronucleus assay.</p>
<p>Topical (dermal) application of 0.0003%–0.03% fluocinonide cream to rats once daily for 13 weeks resulted in a toxicity profile generally associated with long-term exposure to corticosteroids including decreased skin thickness, adrenal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, and severe <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>. A NOAEL could not be determined in this study. In addition, topical (dermal) application of 0.1% fluocinonide cream plus UVR exposure to hairless mice for 13 weeks and 150–900 mg/kg/day of 0.1% fluocinonide cream to minipigs (a model which more closely approximates human skin) for 13 weeks produced glucocorticoid-related suppression of the HPA axis, with some signs of <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> noted in the dermal minipig study. Although the clinical relevance of the findings in animals to humans is not clear, sustained glucocorticoid-related immune suppression may increase the risk of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and possibly the risk for carcinogenesis.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.5"></a><p></p>
<h2>Pregnancy Category C</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.5.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<p class="First">Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.</p>
<p>There are no adequate and well-controlled studies in pregnant women. Therefore, VANOS Cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Nevertheless, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="pediatric"></a><a name="section-7.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and efficacy of VANOS Cream in pediatric patients younger than 12 years of age have not been established; therefore use in pediatric patients younger than 12 years of age is not recommended.</p>
<p>HPA-axis suppression was studied in 4 sequential cohorts of pediatric patients with <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span> covering at least 20% of the body surface area, treated once daily or twice daily with VANOS Cream. The first cohort of 31 patients (mean 36.3% BSA) 12 to &lt; 18 years old; the second cohort included 31 patients (mean 39.0% BSA) 6 to &lt; 12 years old; the third cohort included 30 patients (mean 34.6% BSA) 2 to &lt; 6 years old; the fourth cohort included 31 patients (mean 40.0% BSA) 3 months to &lt; 2 years old. VANOS Cream caused HPA-axis suppression in 1 patient in the twice daily group in Cohort 1, 2 patients in the twice daily group in Cohort 2, and 1 patient in the twice daily group in Cohort 3. Follow-up testing 14 days after treatment discontinuation, available for all 4 suppressed patients, demonstrated a normally responsive HPA-axis. Signs of <span class="product-label-link" type="condition" conceptid="134118" conceptname="Atrophic condition of skin">skin atrophy</span> were present at baseline and severity was not determined making it difficult to assess local skin safety. Therefore, the safety of VANOS Cream in patients younger than 12 years of age has not been demonstrated.</p>
<p>Because of a higher ratio of skin surface area to body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span>, pediatric patients are at a greater risk than adults of HPA-axis suppression and Cushing's syndrome when they are treated with topical corticosteroids. They are therefore also at greater risk of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> during or after withdrawal of treatment. Adverse effects including <span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">striae</span> have been reported with inappropriate use of topical corticosteroids in infants and children.</p>
<p>HPA-axis suppression, Cushing's syndrome, linear <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth retardation</span>, delayed <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">intracranial hypertension</span> have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels and absence of response to cosyntropin (ACTH<span class="Sub">1–24</span>) stimulation. Manifestations of <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">intracranial hypertension</span> include bulging fontanelles, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, and bilateral <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.8"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of VANOS Cream did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">In clinical trials, a total of 443 adult patients with <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span> or plaque-type <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> were treated once daily or twice daily with VANOS Cream for 2 weeks. The most commonly observed adverse events in these clinical trials were as follows:</p>
<a name="i4d01cc05-dd87-4c1f-8e4d-e25a18d9c39a"></a><table width="100%">
<caption><span>Table 3: Most Commonly Observed Adverse Events in Adult Clinical Trials</span></caption>
<col align="left" valign="top" width="37%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="23%">
<thead><tr class="First Last">
<th class="Lrule" align="left">Adverse Event</th>
<th class="Lrule" align="center">VANOS Cream,<br><span class="Italics">once daily</span><br>(n=216)</th>
<th class="Lrule" align="center">VANOS Cream,<br><span class="Italics">twice daily</span><br>(n=227)</th>
<th class="Lrule Rrule" align="center">Vehicle Cream,<br><span class="Italics">once</span> or <span class="Italics">twice daily</span><br>(n=211)</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Lrule" align="center">8/216 (3.7%)</td>
<td class="Lrule" align="center">9/227 (4.0%)</td>
<td class="Lrule Rrule" align="center">6/211 (2.8%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4319311" conceptname="Application site pain">Application Site Burning</span></td>
<td class="Lrule" align="center">5/216 (2.3%)</td>
<td class="Lrule" align="center">4/227 (1.8%)</td>
<td class="Lrule Rrule" align="center">14/211 (6.6%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></td>
<td class="Lrule" align="center">2/216 (0.9%)</td>
<td class="Lrule" align="center">3/227 (1.3%)</td>
<td class="Lrule Rrule" align="center">3/211 (1.4%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">Nasal Congestion</span></td>
<td class="Lrule" align="center">3/216 (1.4%)</td>
<td class="Lrule" align="center">1/227 (0.4%)</td>
<td class="Lrule Rrule" align="center">0</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">Unspecified <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">Application Site Reaction</span></td>
<td class="Lrule" align="center">1/216 (0.4%)</td>
<td class="Lrule" align="center">1/227 (0.4%)</td>
<td class="Lrule Rrule" align="center">3/211 (1.4%)</td>
</tr>
</tbody>
</table>
<p>No other adverse events were reported by more than 1 subject receiving active treatment. The incidence of all adverse events was similar between the active treatment groups and the vehicle control groups. Safety in patients 12 to 17 years of age was similar to that observed in adults.</p>
<p>The following additional local adverse reactions have been reported with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids. These reactions are listed in an approximate decreasing order of occurrence: burning, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, irritation, dryness, <span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">folliculitis</span>, <span class="product-label-link" type="condition" conceptid="443793" conceptname="Hypertrichosis">hypertrichosis</span>, <span class="product-label-link" type="condition" conceptid="4299558" conceptname="Acneiform eruption">acneiform eruptions</span>, hypopigmentation, <span class="product-label-link" type="condition" conceptid="135032" conceptname="Dermatitis due to substances taken internally">perioral dermatitis</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">allergic contact dermatitis</span>, maceration of the skin, <span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">secondary infection</span>, <span class="product-label-link" type="condition" conceptid="134118" conceptname="Atrophic condition of skin">skin atrophy</span>, <span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">striae</span>, and <span class="product-label-link" type="condition" conceptid="4273714" conceptname="Miliaria">miliaria</span>.</p>
<p>Systemic absorption of topical corticosteroids has produced hypothalamic-pituitary-adrenal (HPA) axis suppression manifestations of Cushing's syndrome, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, and glucosuria in some patients.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Topically applied VANOS Cream can be absorbed in sufficient amounts to produce systemic effects (see <span class="Bold"><a href="#precau">PRECAUTIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">For <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>, apply a thin layer of VANOS Cream once or twice daily to the affected skin areas as directed by a physician. Twice daily application for the treatment of <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> has been shown to be more effective in achieving treatment success during 2 weeks of treatment.</p>
<p>For <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span>, apply a thin layer of VANOS Cream once daily to the affected skin areas as directed by a physician. Once daily application for the treatment of <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span> has been shown to be as effective as twice daily treatment in achieving treatment success during 2 weeks of treatment (See <span class="Bold"><a href="#clins">CLINICAL STUDIES</a></span>).</p>
<p>For corticosteroid responsive dermatoses, other than <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> or <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span>, apply a thin layer of VANOS Cream once or twice daily to the affected areas as directed by a physician.</p>
<p><span class="Bold">Treatment with VANOS Cream should be limited to 2 consecutive weeks, and no more than 60 g/week should be used. Do not use more than half of the 120 g tube per week.</span></p>
<p>Therapy should be discontinued when control has been achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">VANOS (fluocinonide) Cream 0.1% is supplied in tubes as follows:</p>
<p>60 g (NDC 54868-6204-0)      <br></p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.1"></a><p></p>
<h2></h2>
<p class="First">Store at controlled room temperature: 15° to 30°C (59° to 86°F).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<h1></h1>
<p class="First">Manufactured for:<br>Medicis, The Dermatology Company<br>Scottsdale, AZ 85256</p>
<p>Manufactured by:<br>Contract Pharmaceuticals Ltd.<br>Mississauga, Ontario<br>Canada L5N 6L6</p>
<p>Made in Canada</p>
<p>U.S. Patents 6,765,001; 7,217,422; 7,220,424 and Patents Pending<br>VANOS is a registered trademark of Medicis Pharmaceutical Corporation.</p>
<p>Prescribing information as of February 2010.</p>
<p>05100002</p>
<p><img alt="Company Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=34b91547-31f6-4043-b91c-16c9ebd81349&amp;name=vanos-02.jpg"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1"></a><p></p>
<p class="First"><span class="Bold">Relabeling of "Additional Barcode Label" by:</span><br>Physicians Total Care, Inc.<br>Tulsa, OK       74146<br></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 60 g Tube Carton</h1>
<p class="First"><span class="Bold">Vanos</span><span class="Sup">®</span><br><span class="Bold">(fluocinonide) cream 0.1%</span></p>
<p>FOR TOPICAL USE ONLY<br>NOT FOR OPHTHALMIC, ORAL,<br>OR INTRAVAGINAL USE</p>
<p>Rx only</p>
<p>60 g</p>
<div class="Figure"><img alt="Principal Display Panel - 60 g Tube Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=34b91547-31f6-4043-b91c-16c9ebd81349&amp;name=6204.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VANOS 		
					</strong><br><span class="contentTableReg">fluocinonide cream</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-6204(NDC:99207-525)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>FLUOCINONIDE</strong> (FLUOCINONIDE) </td>
<td class="formItem">FLUOCINONIDE</td>
<td class="formItem">1 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>DIMETHYL ISOSORBIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYOXYL 100 STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCERYL MONOSTEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CARBOMER HOMOPOLYMER TYPE C</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>DIISOPROPANOLAMINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-6204-0</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">60 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021758</td>
<td class="formItem">11/30/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>658613fc-a080-468d-b588-ce32ece3171b</div>
<div>Set id: 34b91547-31f6-4043-b91c-16c9ebd81349</div>
<div>Version: 1</div>
<div>Effective Time: 20100204</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
